CoChat
Sign Up
Cited by 101

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora

Yang, Libo·2008·Journal of Controlled Release
DOI 10.1016/j.jconrel.2007.10.026
Open this paper in CoChat — free account

Abstract

The fermentation of non-starch polysaccharides by colonic microflora is popular as a triggering mechanism to achieve colon-specific drug delivery in that the existence of colonic microflora is independent of gastrointestinal transit time, pH, and disease conditions, and various delivery systems were developed using this strategy. One of such delivery systems, COLAL technology, has advanced into late stage of product development. However, in vitro characterization of these delivery systems remains a challenge in part because the critical performance indicator is colonic specificity of drug release. Moreover, the dynamic and ecologically diverse features of the colon are difficult to be incorporated into USP dissolution methods. As a result, alternative dissolution approaches have been designed to better represent the colonic conditions, such as utilizing polysaccharide-degrading enzymes, rat caecal contents, human fecal slurries, and multi-stage culture systems. The primary focus of this article is to summarize and review the dissolution testing currently used in characterizing colon-specific delivery systems activated by microflora. A brief description of physiological parameters of the colon relevant to colonic drug release is also presented.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2007.10.026

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 83

  1. Pillay, 1999, Unconventional dissolution methodologies, J. Pharm. Sci., 88, 843, 10.1021/js990139b · DOI
  2. Basit, 2005, Advances in colonic drug delivery, Drugs,, 65, 1991, 10.2165/00003495-200565140-00006 · DOI
  3. Rubinstein, 1995, Approaches and opportunities in colon-specific drug delivery, Crit. Rev. Ther. Drug Carr. Syst., 12, 101, 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.10 · DOI
  4. Yang, 2002, Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation, Int. J. Pharm., 235, 1, 10.1016/S0378-5173(02)00004-2 · DOI
  5. Hovgaard, 1996, Current applications of polysaccharides in colon targeting, Crit. Rev. Ther. Drug Carr. Syst., 13, 185, 10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.10 · DOI
  6. Alizyme Presentation at Lehman Brothers Tenth Annual Global Healthcare Conference, March 21, 2007.
  7. Hanauer, 2004, COLAL-PRED alizyme, Curr. Opin. Investig. Drugs, 5, 1192
  8. Podolsky, 2002, Inflammatory bowel disease, N. Engl. J. Med., 347, 417, 10.1056/NEJMra020831 · DOI
  9. Guarner, 2003, Gut flora in health and disease, Lancet, 360, 512, 10.1016/S0140-6736(03)12489-0 · DOI
  10. Adkin, 1997, The use of scintigraphy to provide “proof of concept” for novel polysaccharide preparations designed for colonic drug delivery, Pharm. Res., 14, 103, 10.1023/A:1012019820603 · DOI
  11. Cummings, 1996, In vivo studies of amylose- and ethylcellulose-coated [13C] glucose microspheres as a model for drug delivery to the colon, J. Control. Release, 40, 123, 10.1016/0168-3659(95)00186-7 · DOI
  12. Tuleu, 2002, Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropylmethylcellulose capsules, Aliment. Pharmacol. Ther., 16, 1771, 10.1046/j.1365-2036.2002.01327.x · DOI
  13. Katsuma, 2004, Scintigraphic evaluation of a novel colon-targeted delivery system (CODES™) in healthy volunteers, J. Pharm. Sci., 93, 1287, 10.1002/jps.20063 · DOI
  14. Cummings, 1991, The control and consequences of bacterial fermentation in the human colon, J. Appl. Bacterial., 70, 443, 10.1111/j.1365-2672.1991.tb02739.x · DOI · Paper page
  15. Gorbach, 1971, Intestinal flora, Gastroenterology,, 60, 1110, 10.1016/S0016-5085(71)80039-2 · DOI
  16. Salyers, 1984, Bacteroides of the lower intestinal tract, Annual Review in Microbiology,, 38, 293, 10.1146/annurev.mi.38.100184.001453 · DOI
  17. Englyst, 1985, Digestion of the polysaccharides of some cereal foods in the human small intestine, Am. J. Clin. Nutr., 42, 778, 10.1093/ajcn/42.5.778 · DOI
  18. Englyst, 1987, Polysaccharide breakdown by mixed populations of human faecal bacteria, FEMS Microbiol. Ecol., 45, 163, 10.1111/j.1574-6968.1987.tb02352.x · DOI
  19. Goldin, 1978, Influence of diet and age on fecal bacterial enzymes, Am. J. Clin. Nutr., 31, S136, 10.1093/ajcn/31.10.S136 · DOI
  20. Goldin, 1977, Alterations in faecal microflora enzymes related to diet, age, lactobacillus supplements, and dimethylhydrazine, Cancer, 40, 2421, 10.1002/1097-0142(197711)40:5+<2421::AID-CNCR2820400905>3.0.CO;2-I · DOI
  21. Hopkins, 2002, Variation in human intestinal microbiota with age, Dig. Liver Dis., 34, S12, 10.1016/S1590-8658(02)80157-8 · DOI
  22. Mueller, 2006, Differences in fecal microbiota in different European study populations in relation to age, gender, and country: a cross-sectional study, Appl. Environ. Microbiol., 72, 1027, 10.1128/AEM.72.2.1027-1033.2006 · DOI · Paper page
  23. Tuohy, 2005, Modulation of the human gut microflora towards improved health using prebiotics – assessment of efficacy, Curr. Pharm. Des., 11, 75, 10.2174/1381612053382331 · DOI
  24. Campbell, 1997, Selected indigestible oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, pH and microflora in rats, J. Nutr., 127, 130, 10.1093/jn/127.1.130 · DOI
  25. Howard, 1995, Dietary fructooligosaccharide, xylooligosaccharide and gum arabic have variable effects on cecal and colonic microbiota and epithelial cell proliferation in mice and rats, J. Nutr., 125, 2604, 10.1093/jn/125.10.2604 · DOI
  26. Hsu, 2004, Xylooligosaccharides and fructooligosaccharides affect the intestinal microbiota and precancerous colonic lesion development in rats, J. Nutr., 134, 1523, 10.1093/jn/134.6.1523 · DOI
  27. Scott, 2003, Manometric techniques for the evaluation of colonic motor activity: current status, Neurogastroenterol. Motil., 15, 483, 10.1046/j.1365-2982.2003.00434.x · DOI
  28. Cook, 2000, Relationships between spatial patterns of colonic pressure and individual movements of content, Am. J. Physiol.: Gastrointest. Liver Physiol., 278, G329
  29. Bampton, 2000, Spatial and temporal organization of pressure patterns throughout the unprepared colon during spontaneous defecation, Am. J. Gastroenterol., 95, 1027, 10.1111/j.1572-0241.2000.01839.x · DOI
  30. Bassotti, 2006, Colonic propulsive and postprandial motor activity in patients with ulcerative colitis in remission, Eur. J. Gastroenterol. Hepatol., 18, 507, 10.1097/00042737-200605000-00008 · DOI
  31. Rao, 2001, Ambulatory 24-h colonic manometry in healthy humans, Am. J. Physiol.: Gastrointest. Liver Physiol., 280, G629
  32. Clemens, 2003, Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome, Am. J. Gastroenterol., 98, 1838, 10.1111/j.1572-0241.2003.07541.x · DOI
  33. Bazzocchi, 1991, Effect of eating on colonic motility and transit in patients with functional diarrhoea. Simultaneous scintigraphic and manometric evaluations, Gastroenterology,, 101, 1298, 10.1016/0016-5085(91)90080-5 · DOI
  34. Bazzocchi, 1990, Postprandial colonic transit and motor activity in chronic constipation, Gastroenterology,, 98, 686, 10.1016/0016-5085(90)90289-D · DOI
  35. Lubowski, 1995, Scintigraphic assessment of colonic function during defaecation, Int. J. Colorectal. Dis., 10, 91, 10.1007/BF00341204 · DOI
  36. Bassotti, 1988, Manometric investigation of high-amplitude propagated contractile activity of the human colon, Am. J. Physiol., 255, G660
  37. Badley, 1993, Noninvasive measurement of human ascending colon volume, Nucl. Med. Common., 14, 485, 10.1097/00006231-199306000-00012 · DOI
  38. Schiller, 2005, Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging, Aliment. Pharmacol. Ther., 22, 971, 10.1111/j.1365-2036.2005.02683.x · DOI
  39. Siewert, 2003, FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms, AAPS PharmSciTech, 4, 10.1208/pt040107 · DOI
  40. Wong, 1997, USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations, J. Control. Release, 47, 173, 10.1016/S0168-3659(97)01633-7 · DOI · Paper page
  41. Hovgaard, 1995, Dextran hydrogels for colon-specific drug delivery, J. Control. Release, 36, 159, 10.1016/0168-3659(95)00049-E · DOI · Paper page
  42. Ji, 2007, In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-targeted pellets of indomethacin, J. Drug Target., 15, 123, 10.1080/10611860601143727 · DOI
  43. Fetzner, 2004, Degradation of raw or film-incorporated β-cyclodextrin by enzymes and colonic bacteria, Eur. J. Pharm. Biopharm., 58, 91, 10.1016/j.ejpb.2004.02.001 · DOI
  44. Pitarresi, 2007, Photocrosslinking of dextran and polyaspartamide derivatives: a combination suitable for colon-specific drug delivery, J. Control. Release, 119, 328, 10.1016/j.jconrel.2007.03.005 · DOI
  45. Ugurlu, 2007, Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture, Eur. J. Pharm. Biopharm., 67, 202, 10.1016/j.ejpb.2007.01.016 · DOI
  46. Li, 2002, In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES™) in multi-pH media using United States Pharmacopeia apparatus II and III, AAPS PharmSciTech, 3, 10.1208/pt030433 · DOI
  47. Yang, 2003, Effect of colonic lactulose availability on the timing of drug release onset in vivo from a unique colon-specific drug delivery system (CODES™), Pharm. Res., 20, 429, 10.1023/A:1022660305931 · DOI
  48. Milojevic, 1996, Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acids pellets, J. Control. Release, 38, 75, 10.1016/0168-3659(95)00112-3 · DOI
  49. Siew, 2000, The potential of organic-based amylose-ethylcellulose film coatings as oral colon-specific drug delivery systems, AAPS PharmSciTech, 1, 10.1208/pt010322 · DOI
  50. McConnell, 2007, Colonic drug delivery using amylose films: the role of aqueous ethylcellulose dispersions in controlling drug release, Cellulose, 14, 25, 10.1007/s10570-006-9078-8 · DOI
  51. Leong, 2002, The formation of colonic digestible films of amylose and ethylcellulose from aqueous dispersions at temperatures below 37 degrees C, Eur. J. Pharm. Biopharm., 54, 291, 10.1016/S0939-6411(02)00121-2 · DOI
  52. Hawksworth, 1971, Intestinal bacteria and the hydrolysis of glycosidic bonds, J. Med. Microbiol., 155, 451, 10.1099/00222615-4-4-451 · DOI
  53. Raghavan, 2002, An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system for colon targeting, Chem. Pharm. Bull., 50, 892, 10.1248/cpb.50.892 · DOI
  54. Rubinstein, 1993, In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier, Pharm. Res., 10, 258, 10.1023/A:1018995029167 · DOI
  55. Van den Mooter, 1994, The relation between swelling properties and enzymatic degradation of azo polymers designed for colon-specific drug delivery, Pharm. Res., 11, 1737, 10.1023/A:1018911316021 · DOI
  56. Rubinstein, 1992, Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content, Pharm. Res., 9, 276, 10.1023/A:1018910128452 · DOI
  57. Katsuma, 2002, Studies on lactulose formulations for colon-specific drug delivery, Int. J. Pharm., 249, 33, 10.1016/S0378-5173(02)00429-5 · DOI
  58. Sinha, 2005, In vivo evaluation of time and site of disintegration of polysaccharide tablet prepared for colon-specific drug delivery, Int. J. Pharm., 289, 79, 10.1016/j.ijpharm.2004.10.019 · DOI
  59. Das, 2006, Cross-linked guar gum hydrogel discs for colon-specific delivery of ibuprofen: formulation and in vitro evaluation, Drug Deliv., 13, 139, 10.1080/10717540500313455 · DOI
  60. Shyale, 2005, Development of colon-targeted albendazole–cyclodextrin–complex drug delivery systems, Drug Dev. Res., 65, 76, 10.1002/ddr.20010 · DOI
  61. Krishnaiah, 2003, Studies on the development of colon targeted oral drug delivery systems for Ornidazole in the treatment of amoebiasis, Drug Deliv., 10, 111, 10.1080/713840359 · DOI
  62. Wei, 2007, Pectin/Ethylcellulose as film coatings for colon-specific drug delivery: preparation and in vitro evaluation using 5-fluorouracil pellets, PDA J. Pharm. Sci. Technol., 62, 121
  63. Prasad, 1998, In vitro evaluation of guar gum as a carrier for colon-specific drug delivery, J. Control. Release, 51, 281, 10.1016/S0168-3659(97)00181-8 · DOI
  64. Jain, 2007, Potential of calcium pectinate beads for target specific drug release to colon, J. Drug Target., 15, 285, 10.1080/10611860601146134 · DOI
  65. Sinha, 2007, Compression coated systems for colonic delivery of 5-fluorouracil, J. Pharm. Pharmacol., 59, 359, 10.1211/jpp.59.3.0004 · DOI
  66. Macfarlane, 1993, Factors affecting fermentation reactions in the large bowel, Proc. Nutr. Soc., 52, 367, 10.1079/PNS19930072 · DOI
  67. Seal, 2001, Comparative gastrointestinal and plasma cholesterol responses of rats fed on cholesterol-free diets supplemented with guar gum and sodium alginate, Br. J. Nutr., 85, 317, 10.1079/BJN2000250 · DOI
  68. Zduńczyk, 2004, Physiological effects of lactulose and inulin in the caecum of rats, Arch. Anim. Nutr., 58, 89, 10.1080/00039420310001656703 · DOI
  69. Noack, 1998, Dietary guar gum and pectin stimulate intestinal microbial polyamine synthesis in rats, J. Nutr., 128, 1385, 10.1093/jn/128.8.1385 · DOI
  70. Gliko-Kabir, 2000, Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation in the rat, J. Control. Release, 63, 129, 10.1016/S0168-3659(99)00180-7 · DOI
  71. Stephen, 1980, Mechanism of action of dietary fibre in the human colon, Nature,, 284, 283, 10.1038/284283a0 · DOI
  72. Moore, 1978, Some current concepts in intestinal bacteriology, Am. J. Clin. Nutr., 31, S33, 10.1093/ajcn/31.10.S33 · DOI
  73. Siew, 2004, Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro, Int. J. Pharm., 273, 129, 10.1016/j.ijpharm.2003.12.015 · DOI
  74. Wilson, 2005, Exploiting gastrointestinal bacteria to target drugs to the colon: an in vitro study using amylose coated tablets, Int. J. Pharm., 300, 89, 10.1016/j.ijpharm.2005.05.010 · DOI
  75. Gibson, 1988, Use of a three-stage continuous culture system to study the effect of mucin on dissimilatory sulfate reduction and methanogenesis by mixed populations of human gut bacteria, Appl. Environ. Microbiol., 54, 2750, 10.1128/aem.54.11.2750-2755.1988 · DOI
  76. Macfarlane, 1998, Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon, Microb. Ecol., 35, 180, 10.1007/s002489900072 · DOI · Paper page
  77. Macfarlane, 1989, Influence of retention time on degradation of pancreatic enzymes by human colonic bacteria grown in a 3-stage continuous culture system, J. Appl. Bacteriol., 67, 520, 10.1111/j.1365-2672.1989.tb02524.x · DOI
  78. Macfarlane, 1989, Influence of mucin on glycosidase, protease and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture system, J. Appl. Bacteriol., 66, 407, 10.1111/j.1365-2672.1989.tb05110.x · DOI
  79. McBain, 1997, Investigations of bifidobacterial ecology and oligosaccharide metabolism in a three-stage compound continuous culture system, Scand. J. Gastroenterol., 32, 32, 10.1080/00365521.1997.11720715 · DOI
  80. Macfarlane, 1998, Polysaccharide degradation by human intestinal bacteria during growth under multi-substrate limiting conditions in a three-stage continuous culture system, FEM Microbiol. Ecol., 26, 231, 10.1111/j.1574-6941.1998.tb00508.x · DOI
  81. McBain, 2001, Modulation of genotoxic enzyme activities by non-digestible oligosaccharide metabolism in in-vitro human gut bacterial ecosystems, J. Med. Microbiol., 50, 833, 10.1099/0022-1317-50-9-833 · DOI
  82. Molly, 1993, Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem, Appl. Microbiol. Biotechnol., 39, 254, 10.1007/BF00228615 · DOI · Paper page
  83. Schacht, 1996, Polymers for colon specific drug delivery, J. Control. Release, 39, 327, 10.1016/0168-3659(95)00184-0 · DOI

Cited by

Sorted by citations

See all 101

Metadata

Authors
Yang, L.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2008-01
Volume
125
Issue
2
Pages
77-86
ISSN
0168-3659
DOI
10.1016/j.jconrel.2007.10.026
Cited by
101
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review